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Abstract
Hyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and
endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on
posttransplant outcomes. Maximum total bilirubin levels (days 0–28) were categorized using maximally selected log rank
statistics to identify a cut off for the endpoint non-relapse mortality (NRM) in a training cohort of 873 patients. EB above this cut
off was correlated with NRM and overall survival (OS) and with pre- and posttransplant Angiopoietin-2, interleukin (IL)18,
CXCL8 and suppressor of tumorigenicity-2 (ST2) serum levels, and the endothelial activation and stress index (EASIX). Clinical
correlations were validated in a sample of 388 patients transplanted in an independent institution. The EB cut off was determined
at 3.6 mg/dL (61.6 µM). EB predicted OS (HR 1.60, 95% CI 1.21–2.12, p < 0.001), and NRM (CSHR 2.14; 1.28–3.56, p=
0.004), also independent of typical endothelial complications such as veno-occlusive disease, refractory acute graft-versus-host
disease, or transplant-associated microangiopathy. However, EB correlated with high Angiopoietin-2, EASIX-pre and EASIX-
day 0, as well as increased levels of posttransplant CXCL8, IL18, and ST2. In summary, EB indicates a poor prognosis. The
association of EB with endothelial biomarkers suggests an endothelial pathomechanism also for this posttransplant complication.
Introduction
Allogeneic stem cell transplantation (alloSCT) elicits non-
relapse mortality (NRM) rates of 10–20%, mostly due to
infectious complications and graft-versus-host disease
(GVHD) [1–5]. Recent findings provide evidence that the
endothelium plays a major role in mortality after infections
and noninfectious critical illnesses [6–15] after alloSCT. One
possible hypothesis highlights a role for endothelial cell
dysfunction set off by inflammatory mechanisms that result in
an altered microcirculation and organ damage [8]. Patients
prone to develop these “ignited” endothelial cell aberrations
can partly be identified prior to conditioning therapy by
markers of preexisting endothelial distress. These endothelial
vulnerability markers [8, 16] predict NRM solely in the
context of a second-hit disease such as GVHD, whereas in all
other patients they exert no impact on outcome.
Angiopoietin-2 (ANG2) constitutes a valuable biomarker
for endothelial vulnerability. ANG2 predicts risk of death
after acute GVHD [8, 17, 18]. Interestingly, in contrast with
other endothelial vulnerability markers such as nitrates,
ST2, asymmetric dimethyl arginine (ADMA), and single
nucleotide polymorphisms in the thrombomodulin (THBD)
and CD40L genes, pretransplant ANG2 was not associated
with transplant-associated thrombotic microangiopathy
(TAM) [15].
Two established forms of endothelial cell dysfunction
after alloSCT are TAM and sinusoidal obstruction syn-
drome/veno-occlusive disease (SOS/VOD). For both com-
plications, the pathophysiology is not understood in detail.
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Also, diagnostic criteria are based on consensus expert
opinions. Accordingly, different diagnostic criteria exist for
both of them that either emphasize higher diagnostic sen-
sitivity or higher specificity [19–23].
Our search for mechanisms of refractory acute GVHD
led us to recognize that endothelial alterations typically
associate with this complication in its most severe form,
even if the diagnostic criteria of TAM were not completely
fulfilled. Indeed, a reduced set of markers characteristic of
TAM (LDH, creatinine, thrombocytes, combined in the
EASIX score) predicted TAM as well as outcome of acute
GVHD and survival after alloSCT [4, 24, 25]. Similarly,
isolated fluid overload in the early posttransplant period,
which is one diagnostic criterion for SOS/VOD, predicted
NRM in the absence of other diagnostic criteria for this
complication [12, 26, 27].
In analogy, we hypothesized that the full set of diag-
nostic criteria for VOD/SOS may identify only the most
acute/severe forms of hepatic endothelial cell dysfunction.
We set out to define the association between hyperbilir-
ubinemia with endothelial/hepatic dysfunction and patient
outcome on a larger scale. We analysed total bilirubin levels
in two independent cohorts of patients with and without
SOS/VOD and evaluated the association with posttransplant
mortality. The endothelial origin of early bilirubinemia (EB)
was investigated by analysing the predictive impact of
EASIX and ANG2, together with the early posttransplant
time course CXCL8, IL18, and ST2.
Methods
Study population
For this retrospective cohort analysis, we analysed a training
cohort and a validation cohort comprising consecutive adult
patients who had undergone alloSCT in two independent
institutions. The training cohort consisted of patients who
were allografted at the University of Heidelberg between 05/
2001 and 12/2013. The validation cohort received alloHSCT
at the Charité—Campus Virchow Klinikum, Berlin between
01/2013 and 12/2015. Patient, laboratory, and clinical data
were accessed retrospectively using clinical data manage-
ment software. Written informed consent to sample and data
collection according to the declaration of Helsinki from all
eligible patients was obtained and sample and data collection
was approved by the responsible Institutional Review
Boards.
GVHD prophylaxis, treatment, and supportive care
Anti-thymocyte globulin (ATG) (days −3 to −1) was given
to patients receiving unrelated donor grafts. Methotrexate
(MTX, days +1, +3, +6) or mycofenolate mofetil (MMF,
days 0–28) were combined with ciclosporin A (CsA) for
prophylaxis of GVHD. Tacrolimus was only used if CsA
was not tolerated. As per in-house policy, all patients from
the Heidelberg cohort transplanted after 01/2010 routinely
received statin-based endothelial protection (SEP): pravas-
tatin (20 mg/d) and ursodeoxycholic acid (UDA) starting at
day −1 before alloSCT in order to reduce calcineurin
inhibitor-associated cardiovascular morbidity [28] and SOS/
VOD [29]. In contrast, in the Berlin cohort SEP was not
routinely used.
Definitions
Acute GVHD was clinically and histologically diagnosed
and graded using standard criteria [30]. Steroid-refractory
GVHD was defined as histologically confirmed disease not
responding to standard prednisone therapy (2 mg/kg body
weight, for intestinal GVHD combined with MMF 2 g/d)
and requiring second-line salvage immunosuppressive
therapy. Thus, our clinical definition also included GVHD
patients that progressed at time points later than 3–7 days
after initiating steroid therapy.
SOS/VOD was defined according to the 2016 EBMT
criteria for SOS/VOD diagnosis in adults [31]. For this
analysis we tracked all patients with bilirubin levels ≥2 mg/
dL between days 0 and 28 after alloSCT and performed in
depth review of electronic clinical records for presence or
absence of the full diagnostic criteria [32].
TAM was diagnosed as reported previously [15] on
the basis of BMT/CTN Toxicity Committee Consensus
Definition for TAM [19] if all of the following parameters
were present: an otherwise unexplained ≥50% rise in
creatinine along with a ≥50% increase in serum lactate
dehydrogenase (LDH) levels (or a preexisting LDH
above 400 U/L), a drop of ≥50% in platelet counts (or a
preexisting platelet count below 50/nl) and at least
2 schistocytes per high power field.
Myeloablative conditioning (MAC) was defined
according to Bacigalupo et al. [33]. However, fractionated
8 Gy total body irradiation (TBI)/Fludarabin was regarded
as reduced intensity conditioning (RIC) [34]. In this
analysis, sequential (aplasia) conditioning regimens were
grouped as MAC.
Risk scores
The Endothelial Activation and Stress Index (EASIX) is a
continuous prognostic marker consisting of three routine
parameters to diagnose TAM (creatinine, lactate dehy-
drogenase, and thrombocyte counts). EASIX is calculated
using the formula: “lactate dehydrogenase (U/L) × creatinine
(mg/dL)/thrombocytes (109 cells per L)” [24, 25].
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The SOS/VOD CIBMTR risk score has been established
to assess the risk of developing SOS/VOD after alloSCT
[35]. It incorporates age, Hepatitis B/C serology, Karnofsky
performance status, use of sirolimus prophylaxis, disease,
disease status at the time of transplant, and conditioning
regimen. It had been developed using the CIBMTR data-
base. We used the “VOD Risk Calculator” [36] and recor-
ded the probability of SOS/VOD development for each
patient in the two independent cohorts when possible.
Cytokine serum levels
Serum of patients recruited to an observational study in
Heidelberg was prospectively collected longitudinally before
and weekly after alloSCT and stored at−80 °C. Serum before
start of conditioning therapy was thawed and Angiopoietin-2
(ANG2), CXCL8 (Interleukin 8), ST2, and Interleukin 18
(IL18) were measured using the R&D human duo set ELISAs
(R&D systems Minneapolis, MN). For the purpose of ana-
lysis, data were grouped when serum was taken on days 0–7,
8–12, 13–21 and “day +28” (days 22–34) after alloSCT.
Statistical analysis
Categorical variables are presented as numbers and per-
centages. Continuous variables are presented as medians
and ranges or interquartile ranges (IQR). Median follow-up
time was estimated using the reverse Kaplan–Meier
method. NRM, time to relapse (TTR), progression-free
survival (PFS), and overall survival (OS) were calculated
from day +28 landmark after alloSCT if not indicated
otherwise. Maximally selected rank statistics based on
Gray’s test for competing risks was used to generate the
optimal cut off for EB between 0 and 28 days after alloSCT
for endpoint NRM [37]. Cumulative incidence function was
applied to estimate the NRM and TTR to account for
competing risks. Cause-specific Cox proportional hazards
modeling was used for the univariable and multivariable
analyses of NRM and TTR. OS and PFS were analyzed by
Cox proportional hazards model. Hazard ratios (HRs) were
calculated to demonstrate the prognostic effect of EB.
Covariates included in multivariable models were age,
diagnosis (myeloproliferative neoplasms (MPN) vs. the
rest), donor relation (mismatched vs. matched), condition-
ing (RIC vs. other), usage of ATG, and recipient sex. The
1000 bootstraps method was used to correct Cox model
estimates (HR and p values) from optimal EB cut off [38].
Prediction error curves were used to assess the performance
of Cox models. Receiver operating characteristic (ROC)
curves and area under the curve (AUC) were used to
evaluate the association of serum markers with EB cut off.
The results on the predictive capacity of EB for differences
in HRs in the training cohort (Heidelberg) were validated in
an independent cohort (Berlin, validation cohort). To assess
differences in the prognostic effect of EB between sub-
groups of patients with statin/UDA prophylaxis or no statin/
UDA prophylaxis, we performed separate Cox regression
models for patients with and without SEP.
All statistical analyses were carried out with statistical
software R, version 3.4.3, together with the R packages
“survival”, version 2.43.3, “cmprsk”, version 2.2-7,
“maxstat”, version 0.7-25, “DescTools” version 0.99.24,
“prodlim”, version 2018.04.18, “pec”, version 2018.7.26,
and “riskRegression”, version 1.43).
Results
Defining early bilirubinemia
For each individual patient of the training cohort, every
bilirubin serum level obtained within the first 4 weeks after
alloSCTs was retrieved from electronic files, and the max-
imum bilirubin level measured between days 0 and 28 was
identified. Maximally selected log rank statistics were per-
formed in the training cohort with endpoint NRM for all
patients who survived the first 28 days after alloSCT. A
maximum bilirubin cut-point at 3.6 mg/dL (61.6 μM) was
identified (Supplementary Fig. 1). Therefore, patients
showing a bilirubin level ≧3.6 mg/dL at any time between
days 0 and 28 were defined as having EB. The first day of
bilirubin levels ≧3.6 mg/dL defined the onset of EB. Of
note, there were nine patients in both cohorts with presence
of mild SOS/VOD but no EB, which is explained by the
definitions of EB (bilirubin levels ≧3.6 mg/dL) and SOS/
VOD (with bilirubin ≧2 mg/dL) (Table 1).
Patient characteristics
Training cohort patients with EB were comparable for age,
statin/UDA prophylaxis, and donor and recipient gender,
but differed significantly from the patients without EB in
terms of other parameters. In particular, EB associated
with myeloproliferative neoplasia (MPN), ATG, MAC,
HLA-mismatches, and high disease stage (Supplementary
Table 1A). Although 898 patients were included in the
study, only 873 patients survived the first 28 days and were
further evaluated in the landmark analyses. The clinical
characteristics of the 873 patients included in the landmark
analyses are shown in Supplementary Table 2. The vali-
dation cohort had patient characteristics similar to that of
the training cohort except for a significantly higher pro-
portion of patients receiving ATG, higher proportion of
related donors, higher disease stage, and a lower proportion
of patients with lymphoma as underlying disease (Table 1).
Similar to the training cohort, patients with EB in the
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validation cohort were enriched for MPN, HLA-mismatches
and high disease stage (Supplementary Table 1B). Patients
with MPN and patients receiving ATG prophylaxis had
higher maximum bilirubin levels between days 0 and 28
(Supplementary Fig. 2), and higher risk of developing EB
(Supplementary Table 1A, B).
EB predicts NRM and OS after alloSCT independent
of VOD
In landmark analyses of outcome after day +28, multi-
variable Cox regression adjusting for age, recipient gender,
ATG prophylaxis, HLA mismatch, disease (MPN vs. other),
MTX and conditioning intensity (RIC vs. MAC or aplasia
conditioning) revealed a significant adverse association of
EB with NRM, PFS and OS, but not with TTR in the
training cohort (Table 2). Cause-specific HRs and p values
for NRM were corrected by 1000 bootstraps. This effect
was similar if patients who developed SOS/VOD until d+
28 were excluded from the analysis (Supplementary
Table 3). The strength of the effect is shown in Fig. 1, and
for patients excluding SOS/VOD in Supplementary Fig. 3.
Prophylaxis with ATG and MPN did not account for the
effect of EB on NRM (Supplementary Fig. 4).
Brier score and concordance index in the multivariable
model revealed EB as a predictor of NRM after day +28
regardless whether VOD patients were included (Supple-
mentary Fig. 5A, B).
Validation with the offset of the multivariable Heidelberg
model in the Berlin validation cohort was successful, i.e.,
the EB effect on NRM after day +28 in patients with or
Table 2 Multivariable Cox regression analysis, training cohort, n= 873, SOS/VOD included.
OS (events= 421) NRM (events= 174) TTR (events= 302) PFS (events= 476)
HR 95% CI p CSHR 95% CI p CSHR 95% CI p HR 95% CI p
EB 1.60 1.21–2.12 <0.001 2.14 1.28–3.56 0.004 0.95 0.65–1.40 0.803 1.46 1.11–1.91 0.006
Age (per year) 1.02 1.01–1.03 <0.001 1.04 1.02–1.05 <0.001 1.00 0.99–1.01 0.402 1.02 1.01–1.03 <0.001
Recipient sex
m vs. f
1.11 0.91–1.36 0.290 1.33 0.96–1.83 0.089 0.98 0.78–1.24 0.866 1.11 0.92–1.34 0.297
HLA mismatch
yes vs. no
1.40 1.11–1.78 0.005 1.78 1.24–2.56 0.002 1.16 0.87–1.55 0.308 1.34 1.07–1.68 0.011
MPN
yes vs. no
0.96 0.65–1.42 0.850 1.44 0.85–2.41 0.172 0.67 0.39–1.13 0.133 0.94 0.65–1.36 0.740
MTX
yes vs. no
0.76 0.61–0.95 0.018 0.66 0.46–0.95 0.023 0.84 0.65–1.09 0.183 0.74 0.60–0.91 0.005
ATG
vs. no ATG
0.73 0.59–0.91 0.004 0.57 0.40–0.80 0.001 0.79 0.62–1.02 0.069 0.78 0.63–0.95 0.015
RIC vs. MAC 0.75 0.57–0.97 0.027 0.73 0.49–1.10 0.133 0.78 0.57–1.06 0.106 0.75 0.58–0.96 0.020
EB early bilirubinemia, OS overall survival, NRM non-relapse mortality, TTR time to relapse, PFS progression-free survival, HR hazard ratio,
CSHR cause-specific hazard ratio, CI confidentiality interval, HLA human leukocyte antigen, HLA mismatch not matched in 10/10 alleles, AML
acute myeloid leukemia, ATG anti-thymocyte globulin, RIC reduced intensity conditioning, MAC myeloablative conditioning, MPN
myeloproliferative neoplasms, MTX methotrexate days 1, 3, 6, P values for NRM were corrected by 1000 bootstraps.










n (%) n (%)
EB, no SOS/VOD 88 (10) 62 (16) 0.075
EB and SOS/VOD 28 (3) 39 (10)
SOS/VOD 43 (5) 44 (11)
SOS/VOD no EB
(Bili < 3.5)
15 (2) 5 (1)
Age (median, range) 54 (17–76) 55 (18–75) 0.081
Statins+UDA (SEP) 501 (56) 0 (0) <0.001
disease stage high [51] 343 (38) 227 (57) <0.001
AML 283 (32) 204 (51) <0.001
ALL 39 (4) 30 (8)
MDS 111 (12) 33 (8)
MPN 66 (7) 43 (11)
Lymphoma 268 (30) 35 (9)
MM 130 (14) 37 (9)
Others 1 (0) 17 (4)
related donor 268 (30) 238 (60) <0.001
Mismatch <10/10 204 (23) 79 (20) 0.245
ATG 576 (64) 361 (90) <0.001
EB early bilirubinemia, SOS/VOD sinusoidal obstruction syndrome/
veno-occlusive disease, SEP statin-based endothelial prophylaxis,
UDA ursodeoxycholic acid, AML acute myeloid leukemia, ALL acute
lymphoblastic leukemia, MDS myelodysplastic syndromes, MPN
myeloproliferative neoplasms, MM multiple myeloma, RIC reduced
intensity conditioning, ATG anti-thymocyte globulin, disease stage
(early, intermediate, late).
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without SOS/VOD was not different in training and vali-
dation cohort (p= 0.471 and p= 0.600, respectively). The
multivariable analyses for the validation cohort are shown
in Supplementary Tables 4A, B.
In the training cohort, the effects of EB on NRM, OS,
and TTR analysed from the day of alloSCT were compar-
able to those obtained after the day +28 landmark (Sup-
plementary Fig. 6).
If considering maximum bilirubin levels as continuous
variable instead as categorical EB, univariable Cox regres-
sion analyses showed significant associations of maximum
bilirubin levels with NRM and OS, but not TTR, in both
cohorts, and also in patients without diagnostic criteria for
SOS/VOD (Supplementary Table 5). Incidence of acute
GVHD and grades 3–4 acute GVHD were not associated
with maximum bilirubin levels in patients without SOS/
VOD (Supplementary Table 5).
EB predicts NRM irrespective of TAM and
irrespective of refractory acute GVHD
Information on TAM and refractory acute GVHD was
available exclusively for the training cohort. Both compli-
cations usually occur within the first 2 years after alloSCT.
We assessed the influence of TAM and/or EB as well as
refractory acute GVHD and/or EB on 2-year NRM from the
day +28 landmark. Irrespective of SOS/VOD, EB remained
significantly associated with increased 2-year NRM if
patients with TAM and those with refractory acute GVHD,
respectively, were excluded (p < 0.001 in all analyses)
(Supplementary Table 6A, B).
EB and blood group mismatches
Blood groups of donors and recipients were grouped into
four categories: complete match, isolated Rh mismatch,
minor mismatch (recipient AB or donor O), and major
mismatch (all other mismatches). Although all mismatches
were associated with mildly increased maximum bilirubin
levels within the first 4 weeks after alloSCT, there was no
association of EB with any grade of blood group incom-
patibility (Supplementary Table 7).
EB and pretransplant biomarkers
In order to test if EB is linked to a preexisting liver damage,
we retrieved liver enzymes prior to starting conditioning
therapy. There was no significant association of EB with
biomarkers of pretransplant liver or cholangiocyte damage
(preconditioning serum levels of alanine aminotransferase
(ALT) and gamma-glutamyltransferase (gGT)) in training
and validation cohort (Supplementary Table 8 and Supple-
mentary Fig. 7).
In contrast, EASIX-pre (Spearman-Rho correl coeff. 0.242,
p < 0.001) and EASIX-d0 (correl coeff. 0.530, p < 0.001) as
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113EB 79 66 62 56 49 46
NONE 760 623 537 491 459 434 413
0 4 8 12
Time after day 28 (Months)
16 20 24
113EB 88 74 69 63 56 54
NONE 760 623 537 491 459 434 413
113EB 79 66 62 56 49 46
Fig. 1 Outcome after
landmark (d+ 28) of the
training cohort (all patients,
including those with SOS/
VOD). EB early bilirubinemia
≥3.6 mg/dL between days 0 and
28; SOS/VOD sinusoidal
obstruction syndrome/veno-
occlusive disease, none, no
SOS/VOD and bilirubin
<3.6 mg/dl; OS overall survival,
NRM non-relapse mortality,
TTR time to relapse.
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bilirubin levels measured between days 0 and 28 in the
training cohort (no VOD). This was not observed for the
CIBMTR-VOD score (correl coeff. 0.057, p= 0.197). Similar
results were obtained in the validation cohort (no VOD):
EASIX-pre, correl coeff. 0.235, p < 0.001; EASIX-d0, correl
coeff. 0.236, p < 0.001, CIBMTR-VOD score, correl coeff.
0.027, p= 0.637. Accordingly, EASIX-pre and EASIX d0
were significantly higher in EB patients with and without
VOD (Fig. 2a, b, Supplementary Fig. 8). EASIX-pre and
EASIX-d0, but not CIBMTR-VOD associated with EB in
ROC analyses in patients with and without VOD (Fig. 3a).
In patients without statin endothelial prophylaxis (SEP),
pretransplant serum levels of ANG2, a marker of endothelial
vulnerability, were significantly increased in patients with EB
as compared to patients without EB in both training and
validation cohort (Fig. 2c). ANG2 associated with EB in ROC
analyses in patients without SEP, but not in patients receiving
SEP (Fig. 3b). In the training cohort time course analyses
of endothelial vulnerability markers showed that ANG2
remained stable in EB patients (no SEP) between pre-
conditioning and day +28, whereas other endothelial markers
such as CXCL8/IL8, ST2, and IL18 significantly increased in
EB patients compared to non-EB patients early after alloSCT
(Fig. 4). Interestingly, patients developing EB in the presence
of statins/UDA had lower maximum ST2 serum levels, but
significantly higher IL18 serum concentrations already before
alloSCT. These high IL18 concentrations remained stable
until day +28, suggesting a preexisting vulnerability that
could not be amended by statins (Fig. 4b).
EB and endothelial prophylaxis with statins and
UDCA
In the training cohort, the incidence of EB (VOD excluded)
was not different in patients with SEP (with pravastatin and
UDA, n= 492) compared to patients without SEP (n= 381)
(12.2% vs. 13.9%). The impact of EB on NRM was sig-
nificantly increased also in patients with SEP (Fig. 5).
Although direct comparison is not possible (no SEP:
patients until 12/2009, SEP: patients starting 01/2010), we
observed a HR of EB of 2.88 for NRM after d+ 28 without
SEP (95% CI 1.90–4.36, p < 0.001), and a HR of 1.92 with
SEP (1.11–3.35, p= 0.021) in patients including SOS/
VOD. For the cohorts without VOD, the HR of EB for
NRM (after d+ 28) were 2.84 without SEP (1.75–4.63 p <
0.001) and 2.01 with SEP (1.11–3.65, p= 0.022) (Fig. 5).
Thus, SEP was not associated with a normalization of the







































































































































Fig. 2 EB and pretransplant endothelial biomarkers. EB and
EASIX scores before conditioning therapy (a) and on day 0 of alloSCT
(b) in patients without diagnostic criteria for SOS/VOD. c EB and
pretransplant Angiopoietin-2 (ANG2) levels in patients with or with-
out SOS/VOD by use of statin/UDA prophylaxis.
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We compared IL18 and EASIX values for patients before
and after (year 2010) introduction of statin prophylaxis.
After 2010 (Patients with SEP), we observed higher levels
of pretransplant IL18 (median 428 (1–7150) vs. 398
(3–6662) ng/mL, Kruskal–Wallis test p= 0.041), higher
EASIX-pre (median 1.3 (0.2–73.8) vs. 1.1 (0.1–41.1), p=
0.001) as well as higher EASIX-d0 (median 7.4 (0.2–195.8)
vs. 2.7 (0.2–99.2), p < 0.001). These findings suggested an
increased fraction of higher-risk patients within the trans-
plantation cohort after 2010.
EASIX and early bilirubinemia
We investigated if EASIX maintained its predictive potential
if EB is taken into account. Supplementary Table 9
demonstrates that EASIX associates with increased risk of
NRM after d+ 28 (EASIX-pre, EASIX-d28) or after acute
GVHD (EASIX-GVHD) irrespective of the diagnosis of EB.
Discussion
This study identifies EB as an independent risk factor for
NRM after alloSCT. Our results are in line with previous
reports about the association between high posttransplant
bilirubin levels and NRM [39–42]. But, the prior studies did
not address the question whether hyperbilirubinemia
occurred due to defined endothelial complications, such as
SOS/VOD or TAM. The association of EB with pre-
transplant markers of endothelial distress and vulnerability
(but not with markers of liver damage) suggest an endo-
thelial contribution to the EB pathogenesis. Of note, EB
retained its adverse impact on NRM even after exclusion of
patients meeting the diagnostic criteria for TAM or SOS.
Endothelial cell dysfunction plays a major role in
transplant-associated complications and mortality following
alloSCT. However, due to the heterogeneity of the endo-
thelial system, a clear definition of endothelial cell dys-
function is difficult. In particular, endothelial cells may be
functionally understood as input-output devices with their
responses differing over space and time similar to the input
signals [43–45]. It is therefore reasonable to assume that
endothelial cell complications are much more multifaceted
than currently assumed in conditions such as TAM or VOD.
Diagnostic criteria of both complications are based on
expert consensus rather than biology, and early intervention
is not possible if strict diagnostic criteria need to be met.
One tool that helps moving diagnosis of endothelial
complications forward on the time axis is EASIX, a set of
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n=896 n=7510.64 (0.59-0.70)
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Fig. 3 EASIX and pretransplant angiopoietin-2 predict EB. a ROC
curves for EASIX-pre, EASIX d0, and the CIBMTR-COD score with
endpoint EB (training cohort). Left panels: SOS/VOD patients are
included, right panels: SOS/VOD patients are excluded. Tables show
area under the curves (AUC) and confidential intervals (95%). b ROC
curves for Angiopoietin-2 (ANG2) with endpoint EB (training cohort,
SOS/VOD included). Left panel: no statin-based endothelial protection
(SEP) with pravastatin and UDA, right panel: patients with SEP.




















ST2, no EB, +statins
ST2, +EB, +statins
IL18, no EB, +statins
IL18, +EB, +statins
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bFig. 4 EB associates with
endothelial cell markers after
alloSCT. a Preconditioning and
day +28 median serum levels of
Angiopoietin-2 (ANG2) and
CXCL8 (IL8) in patients with
EB (no statins, no UDA). ANG2
levels remain high (paired
Wilcoxon test 0.492), whereas
IL8 levels increase (p= 0.025).
b Specific increase of IL8 serum
levels between preconditioning
and day +28 in patients with
EB, but not in patients without
EB (no statins, no UDA).
P values: Kruskal–Wallis tests
comparing EB vs. no EB serum
levels. c, d Time course of ST2
(c) and IL18 (d) median serum
levels before alloSCT (pre) and
within the first 28 days
thereafter. Left panels: no
statins, no UDA. Right panels:
+statins+UDA. Red lines:
patients experiencing EB, blue
lines: no EB. P values:
Kruskal–Wallis tests EB vs.
no EB at the given time span.
N= number of sera of individual
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Fig. 5 EB-associated high NRM is reduced but not normalized by
SEP. Non-relapse mortality after d+ 28 depending on EB and statin-
based endothelial protection (SEP) (training cohort). a All patients
including SOS/VOD. Hazard ratio (HR) of EB without SEP: 2.88
(95% CI 1.90–4.36, p < 0.001 compared with no EB), and 1.92 with
SEP (1.11–3.35, p= 0.021 compared with no EB). b Excluding
patients with SOS/VOD. HR of EB without SEP: 2.84 (1.75–4.63 p <
0.001 compared with no EB) and 2.01 with SEP (1.11–3.65, p= 0.022
compared with no EB).
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day after alloSCT [24, 25]. EASIX predicts TAM, SOS/
VOD, but also death after acute GVHD, death after
alloSCT, and death of low risk myelodysplastic syndromes.
Thus, it is possible that EASIX could serve as a more global
read-out for endothelial cell dysfunction. Similar to LDH,
creatinine and platelet counts that are influenced by a
variety of unrelated clinical conditions (but represent
endothelial dysfunction in the EASIX formula), high bilir-
ubin levels comprise a variety of possible reasons, including
MPN as disease entity, ATG and MTX treatment for
GVHD prophylaxis [46], or blood group mismatches
between donor and recipients. We also observed higher
posttransplant bilirubin in MPN, ATG prophylaxis, and
blood group mismatches, however, EB with the cut off of
3.6 mg/dL defined here retained its predictive capacity even
after multivariable adjustment for these confounders.
The endothelial relation of EB is suggested by its cor-
relation with EASIX-pre, EASIX-d0 (day of transplanta-
tion) and preconditioning ANG2. ANG2 is the endothelial-
derived, stress-inducing antagonist to angiopoietin-1 at the
tie-2 receptor [47, 48]. Several groups reported that ANG2
can predict complications after alloSCT [8, 18, 49]. In our
cohort this hormone associated with outcome after acute
GVHD, but in contrast with ST2, nitrates and genetic risk
factors, ANG2 did not predict TAM [15]. This is the first
report relating pretransplant ANG2 levels to EB. Further-
more, biomarkers predicting cardiovascular mortality and
outcome after alloSCT such as ST2 [50–52] and IL18
[53, 54] showed significantly higher post-transplantation
concentrations in EB patients as compared to patients
without EB, again supporting the endothelial association of
high bilirubin levels.
EB is only one of the clinical diagnostic parameters for
SOS/VOD, and fluid retention is another. Interestingly,
early fluid overload itself was shown to predict NRM after
alloSCT irrespective of VOD/SOS diagnostic criteria [27].
Similar to EB, fluid retention could be predicted by EASIX
[55]. This is consistent with our hypothesis that SOS/VOD
represents one aspect of early endothelial complications, but
others are not detected with the current diagnostic criteria.
Our results are most relevant for designing interventional
studies investigating prevention of endothelial complica-
tions such as SOS/VOD or TAM. In order to demonstrate if
interventional measures, such as defibrotide or statins, are
effective in all or only in high or low risk cohorts, the best-
defined marker of global endothelial risk is currently
EASIX. Drugs that efficiently reduce the incidence of
endothelial complications in high-risk cohorts might not
reach the study endpoint if too many low risk patients were
recruited. In addition, an exclusive focus on compound
diagnoses such as TAM or SOS/VOD may not compre-
hensively reflect the efficacy of drugs that protect the
endothelial cell system.
The limitations of our study are its retrospective nature and
the availability of serum in the training cohort only. Although
the presented correlations are suggestive of an endothelial cell
nature of EB, a causal relationship could not be proven.
In conclusion, EB in the absence of SOS/VOD and/or
TAM is an underrecognized condition associated with a
similar NRM as SOS/VOD. It appears to be an early
complication of endothelial distress that can be predicted by
pretransplant EASIX and ANG2. SEP does not significantly
reduce EB, so that interventional studies targeting the
endothelial cell system are required for endothelial high-risk
patients.
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